Some pharmacodynamics effects of rafoxanide and its interaction with fenbendazole

الملخص EN

This study was carried-out to study the pharmacodynamics characters of rafoxanide with fenbendazole and the interaction between them through studing its effects on, fertility (reproductive organs weights, progressive motility, epididmal sperm count and sperm and abnormalities), Moreover, its effect on some hematological parameters including (WBCs count, differential leucocytic count, RBCs count, and Hb %, platelets count and PCV %), also, the effects on some biochemical parameters including (ALT, AST, and Albumin, total protein, globulin, urea and creatinine) were determined.

Sixty mature Albino rats weighing from 140 – 180 gm each of 4 – 5 month old were used in this study.

The animals were divided into 4 equal groups each of 15 rats, the first group: was left without treatment and kept as a control group, the second group: Given orally Fenbendazole orally at dose level (37.5 mg/Kg), third group: Given orally Rafoxanide at a dose (7.5 mg/Kg) orally) and the fourth group: Fenbendazole (37.5 mg/Kg) + Rafoxanide (7.5 mg/Kg) orally).

Our results concluded that, The using of Fenbendazole for treatment of helminthes parasites improved the index weight of accessary sex glands, tests index weight and epidedymis index weight.

Also, increased the values of WBCs, count, Hb, PCV, serum protein, albumin globulin, serum urea, serum creatinine level observed in Fenbendazole treated group compared with rafoxanide treated group or its combination.

But it decreased the level of sperm motility, sperm count and in Fenbendazole and the higher sperm abnormalities level observed in the group treated with Fenbendazole.

While, the rafoxanide improved the level of sperm motality, count and decrese percentage of abnormalities than Fenbendazole or its combination.

The histopathological results cleared that, there is a severe histological changes in the group treated with Fenbendazole and Rafoxanide than the control group and their combination.